GENTA ACQUIRES JBL SCIENTIFICGenta Inc. of San Diego will announce today that it has acquiredJBL Scientific, a San Luis Obispo, Calif., supplier of specialtybiochemicals., as part of a plan to establish itself as a verticallyintegrated niche pharmaceutical company. Genta, a developerof antisense-based oligonucleotide therapeutics, began aresearch and supply agreement with JBL in 1987

The terms of the deal, completed on Feb. 20, were notdisclosed. JBL will operate as a wholly owned subsidiary andwill continue to sell its product line.

QUADRA DRUG LIGHTS THE WAY TO CANCER CELLS

Quadra Logic Technologies Inc. (QLT) of Vancouver has found away to link its proprietary photosensitive drug BenzoporphyrinDerivative (BPD) to monoclonal antibodies (MAbs) targeted tocancer cells.

QLT showed Monday at the Fifth Symposium on RecentAdvances in Drug Delivery in Salt Lake City that BPD-linkedMAbs were 20 times more likely to target a cancer cell thanBPD alone. At the tumor, BPDs kill cancer cells when activatedby light. Dr. Julia Levy, vice president of discovery at QLT,predicted that this technology will improve the therapeuticpotential of photosensitive drugs.

BAXTER, LIFE TECH. DECLARE DIVIDENDS

Baxter International Inc. (NYSE:BAX) of Deerfield, Ill., increasedits common stock dividend, payable April 1, to 18.5 cents pershare, an increase of 15.6 percent.

Life Technologies Inc. (NASDAQ: LTEK) of Gaithersburg, Md.,will pay a special dividend of $3.50 per share on March 26,1991. This is the first dividend since the 1983 merger ofBethesda Research Laboratories and GIBCO Corp. to form thecompany.

GENICA GETS LICENSE FOR PNS TEST

Genica Pharmaceuticals Corp. of Worcester, Mass., announcedMonday that it has acquired exclusive worldwide licenses fortwo tests to diagnose the neurological disorder paraneoplasticsyndrome (PNS). The tests, developed by Sloan KetteringCancer Center in New York, detect antibodies associated withPNS and reveal cancers linked to the disorder.

(c) 1997 American Health Consultants. All rights reserved.